Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in brain and CNS tumors
- New trial Spotlight
Brain and CNS tumors
Phase 1 trial of GPC2 CAR-T cells targeting GPC2 in pediatric CNS embryonal tumors
This single-site, open-label Phase 1 trial at Stanford University evaluates feasibility, safety, and preliminary activity of autologous GPC2 CAR-T cells delivered via intracerebroventricular infusions in children and…
NCT07087002 First-in-human - New trial Spotlight
Brain and CNS tumors
Phase 1 Trial of M032 IL-12 Producing HSV Oncolytic Virus for Diffuse Midline Glioma
This trial led by MD Anderson Cancer Center evaluates a single intratumoral injection of M032, an IL-12 producing HSV oncolytic virus, in pediatric and adult patients with diffuse midline glioma following standard…
NCT07076498 First-in-human - New trial Spotlight
Brain and CNS tumors
Phase 1 CHAMP1ON: Nivolumab PD-1 Inhibitor for Pediatric High-Grade Glioma
University of Florida is conducting a Phase 1 trial to evaluate safety and feasibility of adjuvant and neoadjuvant ex vivo hematopoietic stem cells (exHSCs), an investigational cell therapy intended to support immune…
NCT07031765 First-in-human - New trial
Brain and CNS tumors
Phase 1 pilot study: Cerebral open flow microperfusion device for intraoperative brain tissue perfusion.
This feasibility study evaluates intraoperative cerebral open flow microperfusion using OFM catheters, tubing, and the MPP102-II pump during planned neurosurgical resection for patients with resectable Grade II-IV…
NCT07089758 First-in-human - New trial
Brain and CNS tumors
Phase 1 Study: Asciminib, a Bcr-Abl inhibitor, with optional sildenafil for brain tumors.
Researchers are evaluating single-dose asciminib, a Bcr-Abl inhibitor, alone or with sildenafil—a phosphodiesterase inhibitor—in a Phase 1 trial for patients with recurrent or progressive resectable brain tumors…
NCT07039760 Exploratory - New trial
Brain and CNS tumors
Phase 1b Definity: Microbubble ultrasound contrast agent for enhanced glioma visualization
This study evaluates DEFINITY UTZ contrast with contrast enhanced ultrasound during glioma surgery to determine if improved visualization can aid tumor resection. Patients with glioma will undergo surgery using this…
NCT07050836 Exploratory - New trial
Brain and CNS tumors
Phase I Trial of Triapine (Ribonucleotide Reductase Inhibitor) with Radiation for Recurrent Gliomas
This study evaluates the safety, side effects, and optimal dose of triapine in combination with daily intensity modulated radiation therapy for patients with recurrent diffuse midline gliomas, astrocytomas…
NCT06860594 Exploratory - New trial
Brain and CNS tumors
Phase 1 trial: Dasatinib tyrosine kinase inhibitor for residual glioma
This Phase 1 trial led by Mayo Clinic in Rochester evaluates safety, tolerability, and potential efficacy of sequential combination regimens – starting with dasatinib plus quercetin, fisetin, and temozolomide – in…
NCT07025226 Exploratory - Trial result
Brain and CNS tumors
Anlotinib Adds ~4 Months PFS to STUPP in Newly Diagnosed GBM
Anlotinib, an oral VEGFR/FGFR/PDGFR multi-kinase inhibitor, was combined with standard chemoradiation (temozolomide + 54–60 Gy RT) in a double-blind, multicenter phase II trial (n = 153). Versus placebo, anlotinib…
- New trial
Brain and CNS tumors
Phase 1 study of bicalutamide, an androgen receptor inhibitor.
This trial investigates whether daily oral bicalutamide combined with brain re-irradiation is safe for patients with recurrent high-grade glioma or glioblastoma. Conducted at the University of Nebraska, the…
NCT06501911 Exploratory - New trial
Brain and CNS tumors
Phase 2 trial of sitagliptin as a DPP-4 inhibitor for Grade 4 gliomas.
This study evaluates sitagliptin given before and after surgery in resectable Grade 4 glioma patients at Case Comprehensive Cancer Center in Cleveland. It is designed to assess if targeting MDSCs via DPP-4 inhibition…
NCT07003542 Exploratory - Trial result
Brain and CNS tumors
B7-H3 CAR-T Infusions Via Dual Ommaya Reservoirs Show 14.6-mo Median OS in Recurrent Glioblastoma
B7-H3 is over-expressed in >70% of glioblastomas, and an intracranial B7-H3–directed autologous CAR-T product was tested in a first-in-human, dose-escalation Phase 1 study (NCT05474378). Nine heavily pre-treated…
NCT05474378 - Trial result
Brain and CNS tumors
Adjuvant TTFields + Pembrolizumab + Temozolomide Lifts mPFS to 12 mo in Newly Diagnosed GBM
TTFields therapy activates type-I-interferon signalling. This single-arm phase 2 study (NCT03405792) evaluated whether adding a PD-1 blockade to the EF-14 backbone could matter. Twenty-six patients,…
NCT03405792 - Trial result
Brain and CNS tumors
CARv3-TEAM-E Dual-EGFR CAR-T Shows 0 DLTs and 6-Month Stable Disease in Recurrent GBM
CARv3-TEAM-E is a second-generation CAR-T construct that targets the mutant neoantigen EGFRvIII and secretes a T-cell–engaging antibody against wild-type EGFR, aiming to overcome glioblastoma’s antigen heterogeneity.…
NCT05660369 - New trial
Brain and CNS tumors
Phase 2 Trial of Ruxolitinib JAK1 Inhibitor in Combination Therapy for Glioblastoma
This randomized Phase 2 trial evaluates the safety and effectiveness of adding ruxolitinib to standard radiation and temozolomide in patients with newly diagnosed glioblastoma. The study features two treatment arms…
NCT06991101 - New trial
Brain and CNS tumors
Phase I 8R-70CAR T cells: IL-8 receptor modified CD70-targeted immunotherapy
A Phase I trial evaluating safety and feasibility of ex-vivo expanded autologous IL-8 receptor-modified CD70 CAR T cell therapy in patients with CD70+ adult glioblastoma and pediatric high-grade gliomas. Sponsored by…
NCT05353530 - New trial
Brain and CNS tumors
Phase 1 Trial of AZD1390 (ATM Inhibitor) with Radiation in Pediatric High-Grade Glioma
Children's Oncology Group is evaluating AZD1390—a small molecule ATM inhibitor that disrupts cancer cell repair processes—administered with focal radiation in pediatric patients with high grade glioma (including…
NCT06894979 - New trial
Brain and CNS tumors
Phase I Trial of CAR T Cells Targeting B7-H3 in Recurrent Glioblastoma
UNC Lineberger is evaluating the safety of intraventricular infusion of investigational B7-H3 directed CAR T cells in patients with recurrent or refractory glioblastoma, with dose-finding in subjects following…
NCT05366179 - New trial
Brain and CNS tumors
Phase II Trial in Glioblastoma: Accelerated RT with Temozolomide Evaluation
Mayo Clinic is comparing short course stereotactic accelerated radiotherapy combined with temozolomide against standard course RT in glioblastoma patients to determine non-inferiority. The trial features integrated…
NCT05781321 - New trial
Brain and CNS tumors
Feasibility of 5-ALA for Fluorescence-Guided Surgery in Pediatric Brain Tumors
This University of Pittsburgh study is assessing 5-ALA—a small molecule that induces tumor fluorescence—for its feasibility in improving tumor visualization during resection in pediatric patients (ages 2 to 18) with…
NCT06907485 - New trial
Brain and CNS tumors
Phase I Trial of Anti-GARP CAR-T in Recurrent High-Grade Glioma
Ohio State is evaluating the safety, optimal dosing, and initial efficacy of anti-GARP CAR-T cell therapy in patients with recurrent grade III/IV gliomas through a treatment protocol that includes apheresis, surgery…
NCT06964737 - New trial
Brain and CNS tumors
Feasibility Study Using FUS with Oral Etoposide in Pediatric Diffuse Midline Glioma
Columbia is assessing whether focused ultrasound can safely open the blood brain barrier to boost oral etoposide delivery in children with progressive diffuse midline glioma, potentially enhancing tumor uptake while…
NCT05762419 - New trial
Brain and CNS tumors
Randomized Study of DOC1021 Dendritic Cell Immunotherapy in Combination with Standard of Care for Newly Diagnosed Adult Glioblastoma
This study evaluates whether adding DOC1021 dendritic cell immunotherapy with pIFN to the standard regimen of surgery, temozolomide, and radiation can improve survival in newly diagnosed IDH-wt glioblastoma patients…
NCT06805305 - New trial
Brain and CNS tumors
Phase I Study: Safety and Feasibility of IL-8 Receptor Modified CD70 CAR T Therapy in pHGG
University of Florida is assessing the safety and feasibility of autologous, IL-8 receptor (CXCR2) modified CD70 CAR T cells in pediatric high-grade gliomas, with dose escalation across three cohorts (1x10^6, 1x10^7,…
NCT06946680 - New trial
Brain and CNS tumors
Phase Ib Study: Evaluating CUE-102 in Recurrent Glioblastoma
Dana-Farber is assessing the safety and recommended dosing of CUE-102—a WT-1-pHLA-IL2-Fc fusion protein—in HLA-A*0201-positive glioblastoma patients at first recurrence, with daily dosing in 21-day cycles and imaging…
NCT06917885 - New trial
Brain and CNS tumors
Phase Ib Trial: ABBV-637/ABBV-155 with ERAS-801 in EGFR-Amplified GBM
Memorial Sloan Kettering Cancer Center is assessing the safety of ABBV-637 or ABBV-155, given alone or with ERAS-801, in recurrent and newly diagnosed EGFR-amplified, IDH-wt glioblastoma, with treatment tailored…
NCT06934889 - New trial
Brain and CNS tumors
MATCHPOINT - Combined Immunotherapy for Relapsed/Progressive Medulloblastoma
University of Florida is piloting a novel immunotherapy approach for children and young adults with relapsed/progressive medulloblastoma (Group 3/4) by combining adoptive cellular therapy (ex vivo expanded…
NCT06514898 - New trial
Brain and CNS tumors
Phase I KIND T Cell Study Targets H3.3K27M Diffuse Midline Glioma
UCSF is launching a first-in-human trial evaluating autologous KIND T cells—engineered to express a TCR specific for the H3.3K27M mutation—following lymphodepletion with cyclophosphamide and fludarabine in…
NCT05478837
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.